

## Product Data Sheet

Product Name: Osanetant (hydrate)

Cat. No.: GC48405

### Chemical Properties

Cas. No.

SMILES O=C(C1=CC=CC=C1)N(CCC2)C[C@]2(C3=CC(Cl)=C(C=C3)Cl)CCCN4CCC(C5=CC=C(C=C5)(N(C)C(C)=O)CC4.O


Formula C<sub>35</sub>H<sub>41</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub>•H<sub>2</sub>O M.Wt 624.7

Solubility DMSO: 15 mg/ml Storage -20°C

General For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the tips ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Evaluation sample solution : ship with blue ice All other available size: ship with RT, or Condition blue ice upon request.

Structure



### Background

Osanetant is a neurokinin-3 (NK<sub>3</sub>) receptor antagonist ( $K_i = 0.21$  nM in CHO cells expressing the human receptor).<sup>1</sup> It is selective for NK<sub>3</sub> over NK<sub>1</sub> and NK<sub>2</sub> receptors ( $K_i$ s = >100 and 0.02  $\mu$ M, respectively).<sup>2</sup> Osanetant inhibits contractions and acetylcholine release induced by neurokinin B in isolated guinea pig ileal strips in a concentration-dependent manner.<sup>1</sup> It inhibits ovalbumin-induced increases in bronchoalveolar lavage fluid (BALF) neutrophil, eosinophil, and lymphocyte infiltration in an ovalbumin-sensitized mouse model of allergic asthma.<sup>3</sup> Osanetant (5 and 10 mg/kg) increases the duration of social interaction, as well as reduces immobility time in the tonic immobility test, indicating anxiolytic-like and antidepressant-like activities, respectively, in gerbils.<sup>4</sup>

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

## Product Data Sheet

---

1.Emonds-Alt, X., Bichon, D., Ducoux, J.P., et al.SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptorLife Sci.56(1)PL27-PL32(1995) 2.Griebel, G., and BeeskÉ, S.Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases•Pharmacol. Ther.133(1)116-123(2012) 3.NÉnan, S., Germain, N., Lagente, V., et al.Inhibition of inflammatory cell recruitment by the tachykinin NK3-receptor antagonist, SR 142801, in a murine model of asthmaEur. J. Pharmacol.421(3)201-205(2001) 4.SalomÉ, N., Stemmelin, J., Cohen, C., et al.Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbilsPharmacol. Biochem. Behav.83(4)533-539(2006)

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: [tech@glpbio.com](mailto:tech@glpbio.com)**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**